MHMS FIJI
MHMS FIJI

Archives 2021

COVID-19 Update – 10-11-2021

Transmission Update:

In the past 7 days, 55 cases were recorded in the central division, 29 new cases in the western division, 2 new cases in the eastern division, and 27 new cases in the northern division. The central division cases constitute 71% of the cumulative total cases nationally, with the western division making up 28% and 1% in the northern and eastern divisions. The 27 new cases recorded in the north are quarantine cases that are part of the repatriation program for the northern division. There is ongoing surveillance conducted for all repatriates.

Since the last update, we have recorded 58 new cases of which 27 new cases were recorded on 09/11/2021 and 31 new cases in the last 24 hours ending at 8 am this morning. The national 7-day rolling average of cases as of 6th November is 16 daily cases.

The weekly incidence rate graph by division indicates a continually declining trend.  Furthermore, the peak weekly incidence in the western division was approximately a third of that in the central division, and the cumulative case numbers are also reflecting a similar difference.

Deaths:

This curve depicts the weekly death rate per 1000 population by divisions since the 2nd wave of this outbreak began in April 2021. Overall the death rate graphs for the Central and Western Divisions indicate a declining trend. The differences between the Central and Western are similar to the incidence of the weekly cases and are likely a reflection of vaccination levels, COVID mitigation measures, and differences in population density.

There are four COVID-19 deaths to report.

The first COVID 19 death to report is of a 72-year-old man from the Western Division. He presented to the Sigatoka Hospital Emergency department in severe respiratory distress and died a few hours later on 16/10/2021. He was not vaccinated.

The second COVID 19 death to report is of a 70-year-old man from the Western Division. He died at home on 01/09/2021 with severe respiratory distress and was not vaccinated.

The third COVID 19 death to report is of a 75-year-old female from the Western Division.  She died at home with severe respiratory distress on 06/08/2021. She was not vaccinated.

The fourth COVID 19 death to report is of a 58-year-old male from the Western Division. He died at home with respiratory distress on 09/08/2021 and was not vaccinated.

Kindly note that deaths from August and September are reported today because of a delay in the issuance of death certificates.

There have been 679 deaths due to COVID-19 in Fiji, with 677 of these deaths during the outbreak that started in April this year. Please note that due to the time required by clinical teams to investigate, classify and report deaths, a 4-day interval is given to calculate the 7 days rolling average of deaths, based on the date of death, to help ensure the data collected is complete before the average is reported. Therefore, as of November 5th, the national 7 days rolling average of COVID-19 deaths per day is 0.1. The 7 days rolling average for COVID-19 deaths per day in the Central and Western Division 1s 0.0 and Eastern Division is 0.1, with a case fatality rate of 1.29%.

We have recorded 578 COVID-19 positive patients who died from serious medical conditions they had before they contracted COVID-19; these are not classified as COVID-19 deaths.

Hospitalisation:

The downward trend in both the new hospital admissions and total admissions in all hospitals admitting COVID-19 patients across the country is consistent with the cases and death trends. The hospital admissions continue on a downward trend indicating a sustained positive response to COVID mitigation measures, Population density differences, and differential Vaccination rates.

Testing:

776 tests have been reported for November 9th, 2021. The 7-day daily test average is 745 tests per day or 0.9 tests per 1,000 population.

The national 7-day average daily test positivity is 3.3%, which is below the WHO recommendation of 5%, and this is illustrated by the lab testing graph. Though we continue testing in high-risk areas, our case numbers and test positivity rate indicate a better control of the community transmission in Fiji through the combined efforts of containment and mitigation measures with ongoing community surveillance.

Epidemic Outlook:

The Ministry of Health continues to monitor the outbreak using indicators such as daily case numbers, hospitalizations, test positivity, and deaths. There is a downward trend across all indicators of the COVID-19 epidemic in Fiji, indicating a positive response to our overall COVID containment and mitigation response.

With borders opening soon, we anticipate our testing numbers to increase from local and international repatriates as well as visitors entering the country.

Occupancy rates in health facilities, the occupancy rate of ICU beds, death rates, and vaccination coverage are indicators to monitor our health response capacity and we see a decreasing trend across indicators from our health facilities with increasing vaccination coverage for adults and 15-17-year-olds in Fiji.

Our weekly testing numbers of over 5,000 are still above the WHO recommended rate of 4 tests per 1,000 population per week (or approx. 3,500 tests per week) and we anticipate continued surveillance and testing in our communities and maritime islands to monitor and detect cases for early intervention.

Public Advisory:

A disease becomes endemic when it is expected to remain persistently present in the community. Some diseases endemic to Fiji are dengue fever and the common cold. These diseases persist at some level in the community and become epidemic when levels go beyond what is determined to be expected and acceptable.

Unfortunately, vaccine-related herd protection is not likely to be as efficient with COVID 19 as seen with some of the traditional vaccine-related diseases like measles. Those eligible must get vaccinated to reduce their risk of infection, severe disease, and death. And we know vaccines are very good in preventing severe disease and deaths.

This lower efficiency in vaccine-related herd immunity also means that the public will need to live with COVID safe measures of masking, hand washing, physical distancing, and good ventilation and/or air cleaning technology. These COVID safe measures remain vital in preventing the need to go back to severely restrictive public health measures.

Adjusting Our Quarantine Protocols

Our quarantine protocols to support international travel have been adjusted to take into account the increasing protection gained by having fully vaccinated persons traveling with other vaccinated persons to highly vaccinated destinations.  This will involve less stringent conditions with more priority given to the testing protocols that ensure early identification and isolation of positive travelers. From the 11th of November, we will be transitioning Border Quarantine Protocols to Border Risk Reduction Protocol for all travelers coming in from Travel Partner Countries This will involve a 3 day stay in a hotel with a test to be done on day 2. A negative result will allow for discharge into the community on day 3.

From the 11th of November incoming travel will be restricted to diplomates, returning residents, permit holders, and those approved by the Covid 19 Risk Mitigation Taskforce. Our Border Risk Reduction Protocol Processes will be trailed during this time and further refined in preparation for the 1st of December. Approvals to home quarantine will be extremely limited during this pilot phase.

Changes to domestic travel quarantine protocols will be announced tomorrow once vaccination coverage data in Vanua Levu and some of the maritime islands is obtained.  The MHMS have escalated preparedness and response plans to mitigate against and manage surges in cases though:

  1. Early warning system set up in all maritime islands and oversight in place to ensure 100% weekly reporting of Acute respiratory illness and Febrile illness from all facilities
  2. Prepositioning of Air, Land, and Sea-based capability to facilitate retrieval of cases within Vanua Levu and from Maritime Islands to sub-divisional and divisional hospitals
  3. The clinical capability has been escalated in health centers and nursing stations to facilitate early diagnosis, monitoring, and referral of sentinel cases.
  4. Testing capacity has been escalated in Viti Levu to support travel to the North and Maritime islands
  5. Clinical Care capability in the 3 divisional hospitals have been escalated
  6. Reviewing and strengthening clinical care protocols for severe disease in all sub-divisional and divisional hospitals

Supporting School Re-opening

COVID-19 poses a lower risk to children however secondary transmission from young school-age children can and does occur in both household and school settings. With good vaccination coverage, high levels of COVID safe adherence, and timely instigation of measure as done in this case, it is possible for us to facilitate a measured containment program whilst continuing the school program whenever we find a positive student in school. This case and similar cases, even if truly positive, will help to refine the implementation of COVID safe measures in schools and help to put in place a quality improvement framework around the program to promote the safe opening of schools.

Students are reminded again of the need to maintain proper masking practices at all times, remain as much as possible in open ventilated spaces when with their friends, and follow all COVID safe measures especially when indoors.

COVID-19 VACCINATION FOR CHILDREN

Public Advisory

Thursday 11th November 2021

COVID-19 VACCINATION FOR CHILDREN AGED 15-17 YEARS OLD

The Ministry of Health and Medical Services is rolling out the COVID-19 vaccination program in schools for children aged 15, 16, and 17 years old. The following is the list of the first dose and second dose venues for the period of November 11th, 2021.

Since the first outbreak of the COVID-19 disease, Fiji has recorded over 45,000 cases with over 500 deaths. To date, more than 540,000 vaccine-eligible Fijians have been fully vaccinated. The Ministry of Health and Medical Services continues to target populations who are at a high risk of COVID-19.

To get vaccinated, the vaccine-eligible child’s parent/guardian is encouraged to register their child on the online vaccination registration system before presenting to vaccination sites.

Parents/guardians can register their child online on this site at VRS Covid-19 Minors Registration (digitalfiji.gov.fj)

Requirements for online registration:

  • Birth Registration Number/ Citizenship Number/Permit Number for the parents/guardian which can be found on the Birth Certificate/Citizenship Certificate/Permit Certificate.
  • Valid photo identification of parent/guardian (Joint FNPF/FRCA, driver’s license, passport, student ID, or FNPF card).
  • Child’s Birth Registration Number/Citizenship Number/Permit Number which can be found on Birth Certificate/Citizenship Certificate/Permit Certificate.

For any queries on online registration, please email vrsupport@digitalfiji.gov.fj / Digital Fiji – 9983728.

For issues with Birth Registration Numbers, contact:

  • Central Division: Registrar General – 9905125/ Deputy Registrar General – 9908953
  • Northern Division: Deputy Divisional Registrar North – 9443320
  • Western Division: Deputy Divisional Registrar West – 9905127

For Citizenship or Permit Number, contact:

  • Digital Fiji – 9983717

Parent/guardian who is unable to register online, can register their child at the vaccination site. Parent/guardian must bring valid photo identification (Joint FNPF/FRCA, driver’s license, passport, student ID, or FNPF card).

All vaccine-eligible children who are residing far from their schools such as boarding school students or those who returned to their villages as a result of COVID-19 disease outbreak and lockdown can go to their nearest school to get their COVID-19 vaccine.

Schools covered Venue Time
Central
Serua/Namosi
All school students aged 15 years and above Old Navua Hospital 9am-3pm
Suva
All school students aged 15 years and above John Wesley Primary School 9am-3pm
Nasinu
All school students aged 15 years and above Rishikul Primary School 9am-3pm
All school students aged 15 years and above Bhawani Dayal Primary School 9am-3pm
Rewa
All school students aged 15 years and above Nausori District School 9am-3pm
Tailevu
All school students aged 15 years and above Tailevu North College 9am-3pm
Western
Rakiraki
All school students aged 15 years and above Rakiraki District School 9am-3pm
All school students aged 15 years and above Barotu Primary school 9am-3pm
Tavua
All school students aged 15 years and above Tavua District Primary 9am-3pm
Ba
All school students aged 15 years and above St Theresa’s Primary school 9am-3pm
Lautoka
All school students aged 15 years and above St Thomas Primary School 9am-3pm
Nadi
All school students aged 15 years and above Nadi Sangam Primary School 9am-3pm
Sigatoka
Korolevu Medical Area
All school students aged 15 years and above Taqaqe District School 9am-3pm
Sigatoka Medical Area
All school students aged 15 years and above Sigatoka Methodist Primary School 9am-3pm
Raiwaqa Medical Area
All school students aged 15 years and above Raiwaqa Health Centre 9am-3pm
Keiyasi Medical Area
All school students aged 15 years and above Namataku District School 9am-3pm
Lomawai Medical Area
All school students aged 15 years and above Naidovi Primary School 9am-3pm
Valley Area
All school students aged 15 years and above Waicoba District School 9am-3pm
Northern
All school students aged 15 years and above Nasea Health Centre 9am-3pm
Cakaudrove
Savusavu
All school students aged 15 years and above Khemendra Central School 9am-3pm
Taveuni
All school students aged 15 years and above Waiyevo Health Centre 9am-3pm
All school students aged 15 years and above Taveuni Central Primary 9am-3pm
All school students aged 15 years and above Vuna Health Centre 9am-3pm

Before going to the vaccination site:

  • Ensure that you are carrying all the necessary documents requested.
  • Ensure that your child eats well; and
  • Carry a bottle of water to stay hydrated.

Please follow all COVID-19 safe measures when going to the vaccination site:

  • Wear a mask.
  • Maintain physical distancing of 2 meters.
  • Avoid crowds.
  • Wash or sanitize hands frequently; and
  • Keep the careFIJI app on your mobile phone always on.
COVID-19 Update – 08-11-2021

Transmission Update:


Since the last update, we have recorded a total of 51 new cases; of which 20 new cases were recorded on 06/11/2021, 9 new cases on 07/11/2021, and 22 new cases in the last 24 hours ending at 8 am this morning.

This epidemic curve depicts the daily positive cases since the 2nd wave of this outbreak began in April 2021. Overall for this 2nd wave, there have been 52,227 cases recorded, with 71% of the cases from the Central Division, 28% of the cases from the Western Division, and 1% of the cases from the Eastern and Northern Division. 

Our National 7- day rolling average is 16 daily cases calculated for 4th November 2021.

Deaths:

We have one COVID-19 death to report.

The COVID-19 death is of an 80-year-old man from Kadavu. He presented to the Vunisea Hospital with cough and respiratory distress. Sadly, he died 4 days after admission on 31/10/2021. He was not vaccinated.

Kindly note we are reporting the death from October today due to the delay in issuance of the death certificate.

There have been 675 deaths due to COVID-19 in Fiji, with 673 of these deaths during the outbreak that started in April this year.

Please note that due to the time required by clinical teams to investigate, classify and report deaths, a 4-day interval is given to calculate the 7 days rolling average of deaths, based on the date of death, to help ensure the data collected is complete before the average is reported.

Therefore, as of November 4th, the national 7 days rolling average of COVID-19 deaths per day is 0.1. The 7 days rolling average for COVID-19 deaths per day in the Central and Western Division is 0.0 and 0.1 in the Eastern Division.

The case fatality rate for COVID-19 deaths in Fiji is 1.29%.

We have also recorded 568 COVID-19 positive patients who died from the serious medical conditions they had before they contracted COVID-19; these are not classified as COVID-19 deaths.

Epidemic Outlook:

The Ministry of Health continues to monitor the outbreak using indicators such as daily case numbers, hospitalizations, test positivity, and deaths. There is a downward trend across all indicators of the COVID-19 epidemic in Fiji, indicating a positive response to our overall COVID containment and mitigation response.

Occupancy rates in health facilities, the occupancy rate of ICU beds, death rates, and vaccination coverage are indicators to monitor our health response capacity and we see a decreasing trend across indicators from our health facilities with increasing vaccination coverage for adults and 15-17-year-olds in Fiji.

Our weekly testing numbers of over 5,000 are still above the WHO recommended rate of 4 tests per 1,000 population per week (or approx. 3,500 tests per week) and we anticipate continued surveillance and testing in our communities and maritime islands to monitor and detect cases for early intervention.

Public Advisory:

A disease becomes endemic when it is expected to remain persistently present in the community. Some diseases endemic to Fiji are dengue fever and the common cold. These diseases persist at some level in the community and become epidemic when levels go beyond what is determined to be expected and acceptable.

Unfortunately, vaccine-related herd protection is not likely to be as efficient with COVID-19 as seen with some of the traditional vaccine-related diseases like measles. Recent data verified and released by the CDC indicate that unvaccinated people with the previous COVID-19 infection were 5 times more likely to have a positive COVID-19 test compared to vaccinated people. As such unvaccinated people cannot rely on herd immunity (or herd protection) nor natural immunity to protect themselves. Those eligible must get vaccinated to reduce their risk of infection, severe disease, and death. And we know vaccines are very good in preventing severe disease and deaths.

This lower efficiency in vaccine-related herd immunity also means that the public will need to live with COVID safe measures of masking, hand washing, physical distancing, and good ventilation and/or air cleaning technology. These COVID safe measures remain vital in preventing the need to go back to severely restrictive public health measures.

The Merck and Pfizer Pill

Much excitement has been generated in the media recently about the Merck Pill or Molnupiravir and the Pfizer pill.

Based on a small trial, Molnupiravir had demonstrated an up to 50% capability in reducing severe disease and death in high risk individuals when given at the onset of infection. Pfizer also reported another pill that is used with an older antiviral drug called Ritonavir. Pfizer reported a 90% reduction in severe disease and hospitalisation when used in high risk persons with mild to moderate disease. Unlike some other potential COVID treatments, either pill could be taken over five days and as part of home-based treatment. Both pills are not for use in patients with diseases severe enough to need hospital admission but seem useful for high-risk individuals, in whom home management would be seen as more ideal.

For Fiji, having access to therapeutic drugs like this would be ideal but we will need to educate people as it has to be used at the onset of mild to moderate disease when symptomatic self-care is appropriate and in settings where recognition of the severe disease is optimal. The drug will need to be so cheap and so safe that it can be used widely in the community. At the moment both drugs seem quite costly although we are aware of initiatives being taken to make Molnupiravir more affordable. There are also safety concerns that need to be well understood. We will need more details of the study itself and a peer-reviewed publication of the report is not yet widely available.

The UK medicines regulator has become the first in the world to approve Molnupiravir. The UK, like many European countries, has been focused on mitigating the risk of severe disease for tens of thousands of vulnerable patients in the upcoming winter.

In essence, both the Merck and Pfizer Pill will work well in settings where health-seeking behavior is at an optimal level. They also provide another layer of protection from severe disease and death apart from covid safe measures, avoiding contained and /or crowded spaces, ensuring good ventilation, and maintaining good vaccination. As such, the pill will need work with the other layers of protection to maximize protection from severe disease and death. To emphasize further, they do not replace any of the layers of protection measures and vaccination remains the most sustainable means to long-term protection from severe disease and death.

We are making preliminary explorations on how we can access stocks once it is more universally endorsed as they do represent a good home-based therapeutic option for high risk individuals with mild to moderate disease.

Supporting School Re-opening

COVID-19 poses a lower risk to children however secondary transmission from young school-age children can and does occur in both household and school settings. We have completed the investigation into the recent student case widely reported in the media. We can now confirm that while the student became unwell with COVID-like symptoms, his illness was not related to COVID-19. The school COVID safe protocols were well adhered to, in that he was picked up by a designated “child protection officer” in the course of oversight surveillance during the day, early notification to health authorities was done and the containment and test protocol was initiated in a timely manner.

With good vaccination coverage, high levels of COVID safe adherence, and timely instigation of measure as done in this case, it is possible for us to facilitate a measured containment program whilst continuing the school program whenever we find a positive student in school. This case and similar cases, even if truly positive,  will help to refine the implementation of COVID safe measures in schools and help to put in place a quality improvement framework around the program to promote the safe opening of schools.

Students are reminded again of the need to maintain proper masking practices at all times, remain as much as possible in open ventilated spaces when with their friends, and follow all COVID safe measures especially when indoors.

COVID-19 SAFETY MEASURES IN SCHOOLS
HEALTH MINISTRY REASSURES PUBLIC OF COVID-19 SAFETY MEASURES IN SCHOOLS
A student at a secondary school in Lautoka, who experienced COVID-19 like symptoms during the first week of Year 12 and Year 13 students resuming school, has been cleared after tests conducted for COVID-19 returned negative.
The Ministry of Health and Medical Services confirms that the student fell ill while attending class, and protocols to treat a student presenting with COVID-19 symptoms in the school environment were immediately activated. The COVID-19 safe protocols included isolating the student to the designated school sickbay, with quick action taken to ensure the student was comfortable and provided with the necessary medical attention. Furthermore, contact tracing and containment protocols were initiated.
It is now evident that given the updated laboratory results, the student’s symptoms were not related to COVID-19. As previously mentioned in our public advice, given the endemic nature of COVID-19 in Fiji, this is a scenario that is expected to occur again and the risk of secondary transmission from school settings will need ongoing mitigation.
Divisional Medical Officer (DMO) West, Dr. Susana Nakalevu said, “Ensuring the safety and protection of students and all school staff from COVID-19 is a priority as schools reopen and classes resume.”
She assures students, parents, and the public that COVID-19 safe measures contained in the Safe School Reopening Guidelines have been instituted in all schools right across the country and all schools and teachers are equipped and ready to respond to any COVID-19 incident occurring within the confines of the school.
Permanent Secretary, Dr James Fong said “The incident in Lautoka provided an opportunity to effectively follow the Safe School Reopening Guidelines and test our response. The school did well in abiding by the guidelines.”
“We thank the school staff for their prompt activation of the Safe School Reopening Guidelines that involved strict monitoring, early detection, and referral of the symptomatic student.”
In his COVID-19 daily statement, PS Health Dr. Fong has stated that parents and guardians can expect that as school reopening continues, there will be some children who will experience and return positive COVID-19 results.
He reminds students, parents, guardians, and the public that we are living with COVID-19 and we must all take responsibility for the safety of our loved ones and our communities.
“Vaccination and receiving two doses protect us and importantly, ensure all vaccine eligible members in our families are fully vaccinated to protect our loved ones and our communities from severe COVID-19.”
The Permanent Secretary reiterated that the practice of COVID-19 safe measures; the proper wearing of masks, washing hands with soap and water or the use of a hand sanitizer, ensuring we cover our coughs and sneezes are all essential to minimizing the risk of transmission in the school environment.
The Permanent Secretary for Education, Heritage, and Arts, Dr. Anjeela Jokhan added that schools will continue to be vigilant in following COVID safe practices. Student safety is paramount as schools open for classes.
COVID-19 Update – 05-11-2021

Transmission Update:

Since the last update, we have recorded a total of 45 new cases; of which 17 new cases were recorded on 04/11/2021 and 28 new cases in the last 24 hours ending at 8 am this morning.

This epidemic curve depicts the daily positive cases since the 2nd wave of this outbreak began in April 2021. Overall, for this 2nd wave, there have been 52,176 cases recorded, with 71% of the cases from the Central Division, 28% of the cases from the Western Division, and 1% of the cases from the Eastern and Northern Division.

Our National 7- day rolling average is 21 daily cases calculated for 1st November 2021.

Deaths:
We do not have any COVID-19 deaths to report.

There have been 674 deaths due to COVID-19 in Fiji, with 672 of these deaths during the outbreak that started in April this year.

Please note that due to the time required by clinical teams to investigate, classify and report deaths, a 4-day interval is given to calculate the 7 days rolling average of deaths, based on the date of death, to help ensure the data collected is complete before the average is reported.

Therefore, as of November 1st, the national 7 days rolling average of COVID-19 deaths per day is 0.3. The 7 days rolling average for COVID-19 deaths per day in the Central Division is 0.3 and 0.0 in the Western Division.

The case fatality rate for COVID-19 deaths in Fiji is 1.29%.

We have also recorded 568 COVID-19 positive patients who died from the serious medical conditions they had before they contracted COVID-19; these are not classified as COVID-19 deaths.

Epidemic Outlook:

The Ministry of Health continues to monitor the outbreak using indicators such as daily case numbers, hospitalisations, test positivity, and deaths. There is a downward trend across all indicators of the COVID-19 epidemic in Fiji, indicating a positive response to our overall COVID containment and mitigation response.

Occupancy rates in health facilities, the occupancy rate of ICU beds, death rates, and vaccination coverage are indicators to monitor our health response capacity and we see a decreasing trend across indicators from our health facilities with increasing vaccination coverage for adults and 15-17-year-olds in Fiji.

Our weekly testing numbers of over 6,000 are still above the WHO recommended rate of 4 tests per 1,000 population per week (or approx. 3,500 tests per week) and we anticipate continued surveillance and testing in our communities and maritime islands to monitor and detect cases for early intervention.

Public Advisory:

A disease becomes endemic when it is expected to remain persistently present in the community. Some diseases endemic to Fiji are dengue fever and the common cold. These diseases persist at some level in the community and become epidemic when levels go beyond what is determined to be expected and acceptable. Determining what that acceptable level of disease is for COVID-19, is a work in progress but in general, it will be at the level which triggers additional control measures, Because COVID-19 is a vaccine-preventable disease, and the vaccines are very good at preventing severe disease and death, in a highly vaccinated population determining and monitoring acceptable levels, or thresholds, goes beyond case numbers. A disease that causes frequent cases in the community (like the common cold) but has a small impact on the numbers of people needing hospitalization or death, and minimal impact on the health system, will require less intervention.  This is why we will be closely monitoring the following indicators: cases, test positivity, hospitalisations, and deaths.

Unfortunately, vaccine-related herd protection is not likely to be as efficient with COVID-19 as seen with some of the traditional vaccine-related diseases like measles. Recent data verified and released by the CDC indicate that unvaccinated people with the previous COVID-19 infection were 5 times more likely to have a positive COVID-19 test compared to vaccinated people. As such unvaccinated people cannot rely on herd immunity (or herd protection) nor natural immunity to protect themselves. Those eligible must get vaccinated to reduce their risk of infection, severe disease, and death. And we know vaccines are very good in preventing severe disease and deaths.

This lower efficiency in vaccine-related herd immunity also means that the public will need to live with COVID safe measures of masking, hand washing, physical distancing, and good ventilation and/or air cleaning technology. These COVID safe measures remain vital in preventing the need to go back to severely restrictive public health measures.

Supporting School Re-opening

COVID-19 poses a lower risk to children however secondary transmission from young school-age children can and does occur in both household and school settings. As school reopening continues, we will expect to find children with COVID-19 symptoms who will test positive. In these instances, an initial investigation will involve:

  1. Establishing whether or not the test reflects an old infection wherein the student is not infectious or a recently acquired infectious case.
  2. A review of the school covid safe conditions
  3. Initiation of the contact tracing investigations which will include immediate swabbing of high-risk contacts

Further actions will be dictated by the findings of this investigatory process. With good vaccination coverage and high levels of COVID safe adherence, it is possible for us to facilitate a measured containment program whilst continuing the school program. It is expected that these cases will help to refine the implementation of COVID safe measures in schools and help to put in place a quality improvement framework around the program to promote the safe opening of schools.

A recent case highlighted in the media is under investigation. Our initial findings suggest that this was a historical case and that the symptoms are unlikely to be related to COVID-19.  We further confirm that no urgent measures were required immediately.

A more comprehensive report will be released once investigations are complete.

Students are reminded again of the need to maintain proper masking practices at all times, remain as much as possible in open ventilated spaces when with their friends, and follow all covid safe measures especially when indoors.

Travel to the North

For the North, the Ministry of Health and Medical Services is supporting a repatriation program and not a social travel program. As such travel for short-term goals is likely to be adversely affected if a person turns out positive while in quarantine. We are doing all we can to improve vaccination coverage in the North and we will review these quarantine measures for local travel after the 11th of November.

We are currently having a logistical challenge in providing the support for testing during quarantine because of the large volume of social travelers that have inundated the repatriation program. We ask those travelers undergoing quarantine in the North to be patient as we continue our protocols to protect the North while the vaccination program continues its rollout.